Blockchain Registration Transaction Record

Silo Pharma Secures Key Patent for PTSD Treatment, Advances Clinical Trials

Silo Pharma (NASDAQ: SILO) gains U.S. patent for PTSD treatment biomarkers, advancing Phase 1 trials for SPC-15. A breakthrough in mental health therapeutics.

Silo Pharma Secures Key Patent for PTSD Treatment, Advances Clinical Trials

This development is crucial as it represents a significant advancement in the treatment of stress-induced affective disorders, including PTSD, a condition affecting millions worldwide. Silo Pharma's innovative approach, particularly with SPC-15, could offer a new, effective treatment option, addressing a critical unmet need in mental health care. The company's progress underscores the potential of psychedelic and novel therapeutics in transforming psychiatric treatment paradigms.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x5ff413d83d6b83fc0298cd30ee0c1ab8bd2cc94da2abb908cd722bc3cc5a080f
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintcoolCyDw-45651e6961f6d5c8a4dfcfec702c620f